145 related articles for article (PubMed ID: 31872454)
1. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
Mizukami Y; Kanemaru H; Nakamura K; Hashigo S; Kajihara I; Miyashita A; Aoi J; Fukushima S; Honda Y; Ihn H
J Dermatol; 2020 Apr; 47(4):e126-e127. PubMed ID: 31872454
[No Abstract] [Full Text] [Related]
2. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
3. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
[No Abstract] [Full Text] [Related]
4. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
5. Targeting
Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
[TBL] [Abstract][Full Text] [Related]
6. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
[TBL] [Abstract][Full Text] [Related]
7. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
Ibrahim T; Routier E; Weill A; Baz M; Robert C
Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
[No Abstract] [Full Text] [Related]
8. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
[TBL] [Abstract][Full Text] [Related]
9. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
[No Abstract] [Full Text] [Related]
10. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
[No Abstract] [Full Text] [Related]
11. BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.
Doxie DB; Greenplate AR; Gandelman JS; Diggins KE; Roe CE; Dahlman KB; Sosman JA; Kelley MC; Irish JM
Pigment Cell Melanoma Res; 2018 Nov; 31(6):708-719. PubMed ID: 29778085
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
13. Response of BRAF
Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
[No Abstract] [Full Text] [Related]
14. [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].
Kopecký J; Kubeček O
Klin Onkol; 2016; 29(2):133-8. PubMed ID: 27081804
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
17. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
Sakai T
Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
Carlino MS; Gowrishankar K; Saunders CA; Pupo GM; Snoyman S; Zhang XD; Saw R; Becker TM; Kefford RF; Long GV; Rizos H
Mol Cancer Ther; 2013 Jul; 12(7):1332-42. PubMed ID: 23645591
[TBL] [Abstract][Full Text] [Related]
19. Complete response for 36 months after BRAF and MEK inhibitor therapy for locally advanced gallbladder melanoma.
Hakim S; Orosey M; Edhi A; Amin M; Cappell MS
Minerva Gastroenterol Dietol; 2019 Sep; 65(3):243-246. PubMed ID: 31115206
[No Abstract] [Full Text] [Related]
20. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]